Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Cutting Off Leukemogenesis: Hydra-like Plasticity of Mature Leukemic Cells.

Bamezai S, Buske C.

Cell Stem Cell. 2019 Aug 1;25(2):167-168. doi: 10.1016/j.stem.2019.07.005.

PMID:
31374194
2.

Glutathione peroxidase 4 and vitamin E control reticulocyte maturation, stress erythropoiesis and iron homeostasis.

Altamura S, Vegi NM, Hoppe PS, Schroeder T, Aichler M, Walch A, Okreglicka K, Hültner L, Schneider M, Ladinig C, Kuklik-Roos C, Mysliwietz J, Janik D, Neff F, Rathkolb B, Hrabé de Angelis M, Buske C, da Silva AR, Muedder K, Conrad M, Ganz T, Kopf M, Muckenthaler MU, Bornkamm GW.

Haematologica. 2019 Jun 27. pii: haematol.2018.212977. doi: 10.3324/haematol.2018.212977. [Epub ahead of print]

3.

Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.

Grunenberg A, Buske C.

Future Oncol. 2019 Aug;15(23):2687-2697. doi: 10.2217/fon-2019-0154. Epub 2019 Jun 11.

PMID:
31184501
4.

Unusual transformation of primary extranodal marginal zone B cell lymphoma of the uterus into a nodal follicular lymphoma grade IIIB.

Grunenberg A, Möller P, Viardot A, Teleanu V, Eiermann D, Buske C, Barth TF.

Ann Hematol. 2019 Mar;98(3):797-799. doi: 10.1007/s00277-019-03598-x. Epub 2019 Jan 26. No abstract available.

PMID:
30683997
5.

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.

Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP.

Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-2018-10-879593. Epub 2018 Dec 6.

PMID:
30523119
6.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ann Oncol. 2019 May 1;30(5):860-862. doi: 10.1093/annonc/mdy466. No abstract available.

PMID:
30520968
7.

Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Salman Z, Buske C.

N Engl J Med. 2018 Nov 15;379(20):1975-1976. doi: 10.1056/NEJMc1809505. No abstract available.

PMID:
30428288
8.

LaminA/C regulates epigenetic and chromatin architecture changes upon aging of hematopoietic stem cells.

Grigoryan A, Guidi N, Senger K, Liehr T, Soller K, Marka G, Vollmer A, Markaki Y, Leonhardt H, Buske C, Lipka DB, Plass C, Zheng Y, Mulaw MA, Geiger H, Florian MC.

Genome Biol. 2018 Nov 7;19(1):189. doi: 10.1186/s13059-018-1557-3.

9.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW.

Lancet Haematol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1.

PMID:
30389036
10.

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159. No abstract available.

PMID:
30285223
11.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. doi: 10.1093/annonc/mdy322. No abstract available.

PMID:
30285219
12.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.

Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.

13.

Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.

Buske C.

Hematol Oncol Clin North Am. 2018 Oct;32(5):821-827. doi: 10.1016/j.hoc.2018.05.009. Epub 2018 Jul 25. Review.

PMID:
30190020
14.

Biomarkers for classification and class prediction of stress in a murine model of chronic subordination stress.

Langgartner D, Füchsl AM, Kaiser LM, Meier T, Foertsch S, Buske C, Reber SO, Mulaw MA.

PLoS One. 2018 Sep 5;13(9):e0202471. doi: 10.1371/journal.pone.0202471. eCollection 2018.

15.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270.

PMID:
29982402
16.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Review.

PMID:
29958569
17.

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients.

Hutchings M, Ladetto M, Buske C, de Nully Brown P, Ferreri AJM, Pfreundschuh M, Schmitz N, Balari AS, van Imhoff G, Walewski J; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Aug 1;29(8):1687-1700. doi: 10.1093/annonc/mdy167.

PMID:
29924296
18.

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.

Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.

Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.

19.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

20.

Revisiting thrombocytopenia in acute promyelocytic leukemia.

Kuchenbauer F, Buske C.

Leukemia. 2018 Jun;32(6):1477-1478. doi: 10.1038/s41375-018-0105-1. Epub 2018 Mar 23. No abstract available.

PMID:
29654268
21.

In Reply.

Buske C.

Dtsch Arztebl Int. 2018 Mar 16;115(11):190. doi: 10.3238/arztebl.2018.0190b. No abstract available.

22.

Impact of age on genetics and treatment efficacy in follicular lymphoma.

Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner AK, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O.

Haematologica. 2018 Aug;103(8):e364-e367. doi: 10.3324/haematol.2018.187773. Epub 2018 Mar 15. No abstract available.

23.

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA.

Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.

24.

Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles.

Mandal T, Beck M, Kirsten N, Lindén M, Buske C.

Sci Rep. 2018 Jan 17;8(1):989. doi: 10.1038/s41598-017-18932-4.

25.

[Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle-cell Lymphoma].

Buske C, Dreyling M.

Dtsch Med Wochenschr. 2018 Jan;143(1):46-51. doi: 10.1055/s-0043-124004. Epub 2018 Jan 9. German. No abstract available.

PMID:
29316585
26.

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.

Herzig JK, Bullinger L, Tasdogan A, Zimmermann P, Schlegel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dolnik A, Schneider E, Kuchenbauer F, Heidel FH, Buske C, Döhner H, Döhner K, Gaidzik VI.

Oncotarget. 2017 Sep 21;8(56):95038-95053. doi: 10.18632/oncotarget.21119. eCollection 2017 Nov 10.

27.

Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.

Schneider E, Staffas A, Röhner L, Malmberg ED, Ashouri A, Krowiorz K, Pochert N, Miller C, Wei SY, Arabanian L, Buske C, Döhner H, Bullinger L, Fogelstrand L, Heuser M, Döhner K, Xiang P, Ruschmann J, Petriv OI, Heravi-Moussavi A, Hansen CL, Hirst M, Humphries RK, Rouhi A, Palmqvist L, Kuchenbauer F.

Haematologica. 2018 Feb;103(2):246-255. doi: 10.3324/haematol.2017.177485. Epub 2017 Dec 7.

28.

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma.

Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trnený M, Wedding U, Fields P; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Mar 1;29(3):544-562. doi: 10.1093/annonc/mdx413.

PMID:
29194473
29.

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

Grunenberg A, Buske C.

Dtsch Arztebl Int. 2017 Nov 3;114(44):745-751. doi: 10.3238/arztebl.2017.0745. Review.

30.

Developmental social isolation affects adult behavior, social interaction, and dopamine metabolite levels in zebrafish.

Shams S, Amlani S, Buske C, Chatterjee D, Gerlai R.

Dev Psychobiol. 2018 Jan;60(1):43-56. doi: 10.1002/dev.21581. Epub 2017 Nov 1.

31.

Super-Resolution Microscopy Unveils Dynamic Heterogeneities in Nanoparticle Protein Corona.

Feiner-Gracia N, Beck M, Pujals S, Tosi S, Mandal T, Buske C, Linden M, Albertazzi L.

Small. 2017 Nov;13(41). doi: 10.1002/smll.201701631. Epub 2017 Sep 18.

PMID:
28922574
32.

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. doi: 10.1093/annonc/mdx219. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261.

PMID:
28881915
33.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.

Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B.

Lancet Haematol. 2017 Aug;4(8):e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14.

PMID:
28712940
34.

Serum Protein Adsorption Enhances Active Leukemia Stem Cell Targeting of Mesoporous Silica Nanoparticles.

Beck M, Mandal T, Buske C, Lindén M.

ACS Appl Mater Interfaces. 2017 Jun 7;9(22):18566-18574. doi: 10.1021/acsami.7b04742. Epub 2017 May 25.

PMID:
28525262
35.

An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.

Buske C, Ogura M, Kwon HC, Yoon SW.

Future Oncol. 2017 May;13(15s):5-16. doi: 10.2217/fon-2017-0153. Review.

36.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096. No abstract available.

PMID:
28453614
37.

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.

Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; & the ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Feb 1;29(2):525. doi: 10.1093/annonc/mdx061. No abstract available.

PMID:
28368466
38.

Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications.

Chakrabortty S, Agrawalla BK, Stumper A, Vegi NM, Fischer S, Reichardt C, Kögler M, Dietzek B, Feuring-Buske M, Buske C, Rau S, Weil T.

J Am Chem Soc. 2017 Feb 15;139(6):2512-2519. doi: 10.1021/jacs.6b13399. Epub 2017 Feb 7.

39.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.

Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.

PMID:
27956157
40.

MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia.

Krowiorz K, Ruschmann J, Lai C, Ngom M, Maetzig T, Martins V, Scheffold A, Schneider E, Pochert N, Miller C, Palmqvist L, Staffas A, Mulaw M, Bohl SR, Buske C, Heuser M, Kraus J, O'Neill K, Hansen CL, Petriv OI, Kestler H, Döhner H, Bullinger L, Döhner K, Humphries RK, Rouhi A, Kuchenbauer F.

Blood Cancer J. 2016 Dec 9;6(12):e508. doi: 10.1038/bcj.2016.110. No abstract available.

41.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
42.

Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?

Buske C.

Lancet Haematol. 2017 Jan;4(1):e4-e5. doi: 10.1016/S2352-3026(16)30163-6. Epub 2016 Dec 1. No abstract available.

PMID:
27914970
43.

VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice.

Gentner E, Vegi NM, Mulaw MA, Mandal T, Bamezai S, Claus R, Tasdogan A, Quintanilla-Martinez L, Grunenberg A, Döhner K, Döhner H, Bullinger L, Haferlach T, Buske C, Rawat VP, Feuring-Buske M.

Oncotarget. 2016 Dec 27;7(52):86889-86901. doi: 10.18632/oncotarget.13563.

44.

Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus.

Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C.

Blood. 2017 Jan 19;129(3):319-323. doi: 10.1182/blood-2016-04-706978. Epub 2016 Nov 8.

45.

Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells.

Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O.

Exp Hematol. 2017 Mar;47:54-63. doi: 10.1016/j.exphem.2016.10.012. Epub 2016 Nov 5.

PMID:
27826122
46.

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.

Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2016 Dec;27(12):2149-2160. doi: 10.1093/annonc/mdw419. Epub 2016 Oct 4. Erratum in: Ann Oncol. 2018 Feb 1;29(2):525.

47.

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v143-v144. No abstract available.

PMID:
27664254
48.

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA.

Blood. 2016 Sep 8;128(10):1321-8. doi: 10.1182/blood-2016-04-711234. Epub 2016 Jul 18. Review.

49.

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.

Vegi NM, Klappacher J, Oswald F, Mulaw MA, Mandoli A, Thiel VN, Bamezai S, Feder K, Martens JHA, Rawat VPS, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Stunnenberg HG, Feuring-Buske M, Buske C.

Cell Rep. 2016 Jul 12;16(2):498-507. doi: 10.1016/j.celrep.2016.05.094. Epub 2016 Jun 23.

50.

GPR56 contributes to the development of acute myeloid leukemia in mice.

Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, Hollnagel M, Bullinger L, Döhner K, Döhner H, Feuring-Buske M, Buske C.

Leukemia. 2016 Aug;30(8):1734-41. doi: 10.1038/leu.2016.76. Epub 2016 Apr 11.

PMID:
27063597

Supplemental Content

Support Center